Table 2.
Comparison of month 0 neutralizing antibody titers (50% plaque reduction neutralization test) in the CYD-TDV vaccine and placebo recipients (pooled) between age cohorts (18–45 vs 9–16 y; 46–50 vs 9–16 y) in the CYD22, CYD65-Overall, CYD65-PHL, CYD65-COL, and CYD14 and CYD15 studies
| CYD22* | CYD65-Overall | CYD65-PHL | CYD65-COL | CYD14 and CYD15 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y) | 18–45 | 9–16 | 18–45 | 46–50 | 9–16 | 18–45 | 46–50 | 9–16 | 18–45 | 46–50 | 9–16 | 9–16 | |
| Sample size | 30 | 52 | 504 | 144 | 282 | 258 | 75 | 142 | 246 | 69 | 140 | 2728 | |
| Average titer | Response rate (95% CI) | 93.3% (78.7 to 98.2%) | 75.0% (61.8 to 84.8%) | 92.9% (90.3 to 94.8%) | 90.3% (84.3 to 94.1%) | 74.8% (69.4 to 79.5%) | 99.6% (97.8 to 99.9%) | 100.0% (95.1 to 100.0%) | 83.1% (76.1 to 88.4%) | 85.8% (80.9 to 89.6%) | 79.7% (68.8 to 87.5%) | 66.4% (58.3 to 73.7%) | 80.1% (78.5 to 81.5%) |
| GM (95% CI) | 156.2 (93.2 to 262.0) | 39.0 (23.7 to 64.1) | 229.8 (201.9 to 261.6) | 207.2 (158.2 to 271.6) | 56.5 (45.0 to 70.8) | 272.3 (242.8 to 305.5) | 277.1 (228.6 to 335.9) | 76.2 (57.0 to 101.7) | 192.4 (152.1 to 243.3) | 151.1 (89.7 to 254.5) | 41.7 (29.5 to 58.8) | 94.1 (87.6 to 101.1) | |
| GM ratio (95% CI) | 4.00 (1.98 to 8.10) | Ref | 4.07 (3.14 to 5.28) | 3.67 (2.58 to 5.22) | Ref | 3.58 (2.62 to 4.88) | 3.64 (2.58 to 5.14) | Ref | 4.62 (3.05 to 6.99) | 3.63 (1.95 to 6.75) | Ref | - | |
| GM ratio (95% CI) | 1.66 (0.99 to 2.80) | - | 2.44 (2.11 to 2.83) | 2.20 (1.67 to 2.91) | - | 2.89 (2.53 to 3.31) | 2.94 (2.40 to 3.62) | - | 2.04 (1.60 to 2.61) | 1.61 (0.95 to 2.72) | - | Ref | |
| DENV-1 | Response rate (95% CI) | 90.0% (74.4 to 96.5%) | 61.5% (48.0 to 73.5%) | 89.9% (86.9 to 92.2%) | 87.5% (81.1 to 91.9%) | 61.0% (55.2 to 66.5%) | 97.7% (95.0 to 98.9%) | 98.7% (92.8 to 99.8%) | 68.3% (60.3 to 75.4%) | 81.7% (76.4 to 86.0%) | 75.4% (64.0 to 84.0%) | 53.6% (45.3 to 61.6%) | 71.5% (69.8 to 73.2%) |
| GM (95% CI) | 215.5 (107.1 to 433.6) | 44.9 (24.0 to 83.9) | 286.0 (242.2 to 337.7) | 243.3 (176.1 to 336.1) | 58.7 (44.3 to 77.8) | 295.7 (249.7 to 350.2) | 308.9 (229.7 to 415.5) | 65.7 (45.8 to 94.3) | 276.2 (206.2 to 369.8) | 187.6 (103.3 to 340.6) | 52.3 (33.8 to 80.9) | 116.1 (106.3 to 126.9) | |
| GM ratio (95% CI) | 4.80 (1.91 to 12.09) | Ref | 4.87 (3.52 to 6.75) | 4.14 (2.70 to 6.35) | Ref | Ref | 5.28 (3.13 to 8.91) | 3.59 (1.72 to 7.47) | Ref | - | |||
| GM ratio (95% CI) | 1.86 (0.92 to 3.75) | - | 2.46 (2.04 to 2.97) | 2.09 (1.50 to 2.93) | - | 2.55 (2.10 to 3.08) | 2.66 (1.95 to 3.62) | - | 2.38 (1.75 to 3.23) | 1.62 (0.88 to 2.95) | - | Ref | |
| DENV-2 | Response rate (95% CI) | 93.3% (78.7 to 98.2%) | 63.5% (49.9 to 75.2%) | 92.1% (89.4 to 94.1%) | 88.2% (81.9 to 92.5%) | 67.4% (61.7 to 72.6%) | 4.50 (3.02 to 6.69%) | 4.70 (2.95 to 7.47%) | 76.1% (68.4 to 82.3%) | 84.6% (79.5 to 88.5%) | 75.4% (64.0 to 84.0%) | 58.6% (50.3 to 66.4%) | 76.0% (74.3 to 77.5%) |
| GM (95% CI) | 290.3 (163.6 to 515.0) | 70.6 (37.3 to 133.8) | 301.1 (260.1 to 348.5) | 278.3 (202.4 to 382.7) | 67.4 (52.3 to 86.9) | 376.6 (329.0 to 430.9) | 372.7 (292.7 to 474.6) | 95.9 (68.5 to 134.2) | 238.1 (183.2 to 309.4) | 202.6 (110.0 to 373.1) | 47.2 (32.4 to 68.7) | 137.6 (126.6 to 149.5) | |
| GM ratio (95% CI) | 4.11 (1.77 to 9.56) | Ref | 4.47 (3.33 to 5.98) | 4.13 (2.75 to 6.20) | Ref | 3.93 (2.73 to 5.64) | 3.89 (2.57 to 5.87) | Ref | 5.05 (3.20 to 7.97) | 4.29 (2.10 to 8.76) | Ref | - | |
| GM ratio (95% CI) | 2.11 (1.18 to 3.76) | - | 2.19 (1.85 to 2.59) | 2.02 (1.46 to 2.81) | - | 2.74 (2.34 to 3.21) | 2.71 (2.10 to 3.50) | - | 1.73 (1.31 to 2.28) | 1.47 (0.79 to 2.73) | - | Ref | |
| DENV-3 | Response rate (95% CI) | 93.3% (78.7 to 98.2%) | 65.4% (51.8 to 76.8%) | 92.1% (89.4 to 94.1%) | 89.6% (83.5 to 93.6%) | 69.1% (63.5 to 74.3%) | 98.8% (96.6 to 99.6%) | 98.7% (92.8 to 99.8%) | 77.5% (69.9 to 83.6%) | 85.0% (80.0 to 88.9%) | 79.7% (68.8 to 87.5%) | 60.7% (52.4 to 68.4%) | 75.0% (73.4 to 76.6%) |
| GM (95% CI) | 132.2 (76.7 to 227.7) | 33.4 (20.4 to 54.8) | 253.3 (219.5 to 292.3) | 226.7 (170.9 to 300.8) | 76.1 (58.1 to 99.6) | 314.4 (270.4 to 365.5) | 320.5 (246.2 to 417.1) | 117.4 (81.6 to 168.8) | 202.0 (158.0 to 258.1) | 155.6 (93.6 to 258.9) | 49.1 (33.2 to 72.4) | 108.3 (99.8 to 117.6) | |
| GM ratio (95% CI) | 3.95 (1.92 to 8.15) | Ref | 3.33 (2.45 to 4.51) | 2.98 (2.02 to 4.40) | Ref | 2.68 (1.81 to 3.97) | 2.73 (1.75 to 4.27) | Ref | 4.12 (2.60 to 6.51) | 3.17 (1.68 to 6.00) | Ref | - | |
| GM ratio (95% CI) | 1.22 (0.70 to 2.11) | - | 2.34 (1.98 to 2.76) | 2.09 (1.56 to 2.81) | - | 2.90 (2.44 to 3.45) | 2.96 (2.25 to 3.90) | - | 1.86 (1.44 to 2.41) | 1.44 (0.86 to 2.41) | - | Ref | |
| DENV-4 | Response rate (95% CI) | 83.3% (66.4 to 92.7%) | 50.0% (36.9 to 63.1%) | 89.3% (86.3 to 91.7%) | 88.9% (82.7 to 93.0%) | 61.3% (55.5 to 66.8%) | 97.3% (94.5 to 98.7%) | 98.7% (92.8 to 99.8%) | 72.5% (64.7 to 79.2%) | 80.9% (75.5 to 85.3%) | 78.3% (67.2 to 86.4%) | 50.0% (41.8, 58.2) | 68.0% (66.3 to 69.8%) |
| GM (95% CI) | 72.1 (38.4 to 135.3) | 21.9 (13.9 to 34.6) | 127.9 (112.2 to 145.9) | 120.2 (92.5 to 156.2) | 33.7 (27.2 to 41.8) | 157.1 (136.6 to 180.7) | 159.8 (123.3 to 207.1) | 45.5 (34.2 to 60.4) | 103.1 (82.5 to 128.9) | 88.2 (55.4 to 140.6) | 24.9 (18.1 to 34.2) | 45.3 (42.3 to 48.5) | |
| GM ratio (95% CI) | 3.29 (1.53 to 7.08) | Ref | 3.79 (2.95 to 4.87) | 3.56 (2.54 to 4.99) | Ref | 3.46 (2.52 to 4.74) | 3.51 (2.40 to 5.15) | Ref | 4.14 (2.81 to 6.09) | 3.54 (2.02 to 6.20) | Ref | - | |
| GM ratio (95% CI) | 1.59 (0.85 to 3.00) | - | 2.83 (2.44 to 3.28) | 2.66 (2.03 to 3.48) | - | 3.47 (2.97 to 4.05) | 3.53 (2.70 to 4.61) | - | 2.28 (1.80 to 2.88) | 1.95 (1.22 to 3.12) | - | Ref | |
DENV, dengue virus; GM, geometric mean; Ref, reference group in the denominator.
The CYD22 response rates, GMs and GM ratios were previously reported in11 and are included here for comparison. CYD14 and CYD15 results shown are for controls only (i.e. VCD-free through month 25).
For CYD65 (that did not have a placebo group), titers were pooled over all vaccine groups (1, 2 or 3 vaccinations).